Egyptian practical guidance in lipid management 2020

Taha, Hesham; Badran, Hala Mahfouz; Kandil, Hossam; Farag, Nabil; Oraby, Abbas; Sharkawy, Magdy El; Shokry, Khaled; Fawzy, F I; Mahrous, Hossam; Bahgat, Juliette; Samy, Mina; Shaker, Mirna Mamdouh

doi:10.1186/s43044-021-00140-1

Cited by 9 publications

(9 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The postprandial rise in TG is usually small, between 12 and 27 mg/dL. Fasting lipid testing is preferred in patients with metabolic syndrome, family history of premature ASCVD or genetic lipid disorders, non-fasting TG ≥ 400 mg/dL and to assess adherence to lifestyle interventions and lipid lowering medications [ 7 , 9 , 18 , 23 , 24 ].…”

Section: Scope Of the Articlementioning

confidence: 99%

See 1 more Smart Citation

Egyptian practical guidance in hypertriglyceridemia management 2021

et al. 2021

Self Cite

View full text Add to dashboard Cite

Hypertriglyceridemia (HTG) is a very common, yet underappreciated problem in clinical practice. Elevated triglyceride (TG) levels are independently associated with atherosclerotic cardiovascular disease (ASCVD) risk. Furthermore, severe HTG may lead to acute pancreatitis. Although LDL-guided statin therapy has improved ASCVD outcomes, residual risk remains. Recent trials have demonstrated that management of high TG levels, in patients already on statin therapy, reduces the rate of major vascular events. Few guidelines were issued, providing important recommendations for HTG management strategies. The goal of treatment is to reduce the risk of ASCVD and acute pancreatitis. The management stands on lifestyle modification, detection of secondary causes of HTG and pharmacological therapy, when indicated. In this guidance we review the causes and classification of HTG and summarize the current methods for risk estimation, diagnosis and treatment. The present guidance provides a focused update on the management of HTG, outlined in a simple user-friendly format, with an emphasis on the latest available data.

show abstract

Section: Scope Of the Articlementioning

confidence: 99%

“…We have previously published a consensus statement on the management of lipids [ 18 ]. We felt that there was a need to address an ignored and frequently overlooked part in the management of dyslipidemia which was hypertriglyceridemia.…”

Section: Introductionmentioning

confidence: 99%

Egyptian practical guidance in hypertriglyceridemia management 2021

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…In Egypt, 46% of overall deaths are related to cardiovascular diseases (CVD) [ 17 , 18 ]. Dyslipidemia increases the risk of CVD.…”

Section: Introductionmentioning

confidence: 99%

“…Dyslipidemia increases the risk of CVD. Several studies showed that high blood cholesterol had been found in 37% of Egyptians [ 18 – 20 ]. Hydroxymethyl glutaryl-CoA (HMG-CoA) reductase inhibitors (statins) are the primary pharmacotherapy for dyslipidemia [ 21 ].…”

Section: Introductionmentioning

confidence: 99%

Association between CYP3A4/CYP3A5 genetic polymorphisms and treatment outcomes of atorvastatin worldwide: is there enough research on the Egyptian population?

Maslub,

Radwan,

Daud

et al. 2023

Eur J Med Res

View full text Add to dashboard Cite

Introduction Atorvastatin is regarded as the most frequently prescribed statin worldwide for dyslipidemia. However, clinical response and risk of adverse effects to statin therapy are associated with genetic variations. Numerous research linked statins pharmacokinetics (PK) variations to genetic polymorphisms in cytochromes P450 (CYPs) metabolic enzymes. Objective This article reviews the association between CYP3A4/5 genetic variations and response to atorvastatin therapy globally, which includes atorvastatin PK, and the risk for adverse reactions, with a hint to the Egyptians. Methods Up to March 30, 2022, electronic medical databases like PubMed, Web of Science, MEDLINE, and Egyptian Knowledge Bank (EKB) were searched. All articles that highlighted the relationship between CYP3A4/5 genetic polymorphisms and atorvastatin efficacy/safety profile were included in this review. Results Initially, 492 articles were retrieved after an exhaustive search. There were 24 articles included according to the inclusion criteria. Findings of association studies of CYP3A4/5 genetic polymorphisms with response to atorvastatin varied among different ethnicities. CYP3A4*1B was associated with better therapeutic outcomes after atorvastatin therapy in Chileans and vice versa in Americans. Caucasians with myalgia while using atorvastatin were at significant risk of suffering severe muscle damage if they were carriers of CYP3A5*3/*3. As far as we can report for the Egyptian population, the impact of CYP3A4/5 genetic variations on the response to atorvastatin therapy was understudied. Conclusion More pharmacogenetic studies amongst diverse populations worldwide, like the Egyptian population, are necessary to detect further atorvastatin-gene interactions. Graphical Abstract

show abstract

“…Approximately 37% percent of population in Egypt is subjected to have higher blood cholesterol levels as per the observation from various researchers. Many risk factors can be expected to evolve, which are responsible for the development of atherosclerotic cardiovascular diseases; therefore, it becomes essential factor to assess the nature of cardiovascular risk before it becomes imperative 28 . As per the definition stated in the background, Hyperlipidemia is a medical condition which is characterized by the observation of increase any or all lipids profile and lipoproteins in the blood.…”

Section: Introductionmentioning

confidence: 99%

The effect of herbal treatment of Hyphaene Thebaica (Doum) and Nelumbo Nucifera (Lotus) on Induced Hyperlipidemia and Hypertension in Male Wistar Albino Rats

Elmahdy M.F,

Adris M.A,

O. Belih S.S

2022

MLU

View full text Add to dashboard Cite

Hyperlipidemia is a condition in medical terms where any lipid profile or else the lipoproteins are increased in the blood stream. Elevated LDL is risky and the best indicator of atherosclerosis risk. Hypertension is one of the most associated disease with dyslipidemia. For HDL-C, the risk of hypertension is supposed to be increased at such low levels. There are various medicinal plants, which are supposed to be a very important source for upcoming chemical substances which are having the potential for therapeutic effects. There are various phenolic as well as flavonoids substances present in Hyphaene Thebaica (Doum). These ingredients usually work as an antioxidant that are very helpful to provide a control towards hyperlipidemic. Hyphaene Thebaica has antimicrobial, antidiabetic antihypertensive, hypolipidemic and antioxidant effects. Yet another element called as Nelumbo Nucifera (Lotus) is very useful for medicinal purposes in terms of Oriental medicine. These plants are very hypolipidemic, antioxidant activity, antipyretic, antiplatelet activity and hypoglycemic activity.Objective of the study: to estimate the effects of doum and lotus methanolic extracts on hyperlipidemia, hypertension and diabetes on lipid profile parameters and hypertension parameters like angiotensin converting enzyme and aldosterone. Material and Methods:The study in this paper was done on fourth rats with the species of Wistar Albino. These rats are divided in to four groups and all are male samples. First one was control group and hyperlipidemia and hypertension induced in three groups. Feeding hyperlipidemic and hypertensive rats with extract of doum in third group and lotus extract in fourth group. Results:The effect of both extracts on lipid profile parameters, Angiotensin converting enzyme and aldosterone were parallel in significant lowering them. Doum had strong effect on body weight but lotus had strong effect on fasting blood glucose level.

show abstract

Egyptian practical guidance in lipid management 2020

Cited by 9 publications

References 34 publications

Egyptian practical guidance in hypertriglyceridemia management 2021

Egyptian practical guidance in hypertriglyceridemia management 2021

Association between CYP3A4/CYP3A5 genetic polymorphisms and treatment outcomes of atorvastatin worldwide: is there enough research on the Egyptian population?

The effect of herbal treatment of Hyphaene Thebaica (Doum) and Nelumbo Nucifera (Lotus) on Induced Hyperlipidemia and Hypertension in Male Wistar Albino Rats

Contact Info

Product

Resources

About